Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab plus Depigoid versus Depigoid alone in seasonal allergic asthma with seasonal allergic rhinoconjunctivitis
2005-003860-47Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and allergic rhinoconjunctivitis (ARC) comparing Xolair + Depigoid with Placebo + Depigoid (2 arms). Primary endpoint: Mean daily symptom load. Started Nov 2005; status: completed.
02
Drugs
omalizumabDepigoid
03
Conditions
asthmaallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2005-003860-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003860-47.